BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC

Cetuximab, the FDA-approved anti-EGFR antibody for head and neck squamous cell carcinoma (HNSCC), has displayed limited efficacy due to the emergence of intrinsic and acquired resistance. We and others have demonstrated that cetuximab resistance in HNSCC is driven by alternative receptor tyrosine ki...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Res
Main Authors: Leonard, Brandon, Brand, Toni M, O’Keefe, Rachel A, Lee, Eliot D, Zeng, Yan, Kemmer, Jacquelyn D, Li, Hua, Grandis, Jennifer R, Bhola, Neil E
格式: Artigo
語言:Inglês
出版: 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6072571/
https://ncbi.nlm.nih.gov/pubmed/29792310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-0459
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍